In the Claims:

This listing of the claims will replace all prior versions, and listings, of the claims in the application:

1.-70. **(Canceled)**

71. **(New)** A method of treating or ameliorating rheumatoid arthritis or one or more symptoms thereof, said method comprising administering to a subject in need thereof a prophylactically or therapeutically effective amount of an $\alpha_v\beta_3$ specific antibody comprising a VH CDR1(SEQ ID NO:1), VH CDR2(SEQ ID NO:2), VH CDR3(SEQ ID NO:3), VL CDR1(SEQ ID NO:4), VL CDR2(SEQ ID NO:5) and VL CDR3(SEQ ID NO:6) or an antigen binding fragment thereof, and a prophylactically or therapeutically effective amount of a TNF-α antagonist, wherein the TNF-α antagonist is infliximab or an antigen binding fragment thereof.

72. **(New)** The method of claim 71, wherein the $\alpha_v\beta_3$ specific antibody is a human or humanized antibody.

73. **(New)** The method of claim 71, wherein the $\alpha_v\beta_3$ specific antibody or an antigen binding fragment thereof administered to the subject is a dosage of about 0.1 mg/kg to 10 mg/kg.

74. **(New)** The method of claim 71, wherein the amount of infliximab or an antigen binding fragment thereof administered to the subject is a dosage of about 0.1 mg/kg to 10 mg/kg.

75. **(New)** The method of claim 71, wherein the $\alpha_v\beta_3$ specific antibody or antigen binding fragment thereof or infliximab or an antigen binding fragment thereof is administered orally, topically, intravenously, intramuscularly or subcutaneously to the subject.

76. **(New)** The method of claim 71, wherein the subject is a human.